PROVECTUS BIOPHARMACEUTICALS, INC.
PVCTOTCHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $336,108 | $617,140 | $557,710 | $989,042 | — | — |
| Operating income | −$5.3M | −$4.5M | −$2.9M | −$3.4M | −$4.7M | −$5.0M |
| Net income | −$5.4M | −$4.7M | −$3.1M | −$3.6M | −$5.5M | −$6.7M |
| Total assets | $697,502 | $1.0M | $1.4M | $2.0M | $3.5M | $589,201 |
| Total liabilities | $7.0M | $7.0M | $9.0M | $8.3M | $7.7M | $30.8M |
| Equity | −$6.3M | −$6.0M | −$7.6M | −$6.2M | −$4.2M | −$30.2M |
| EPS (diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | — |
| Shares out. | 420.3M | 419.5M | 419.5M | 419.4M | 403.6M | 390.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1575.3%
- Net margin
- −1615.8%
- Return on equity
- 86.2%
- Return on assets
- −778.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 1003.6%
- Debt / equity
- —
- Book value / share
- $-0.01
- Revenue growth (YoY)
- −45.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1340.02distress
- Accruals / assets
- −301.8%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 16, 2017
- NT 10-Kmissed a reporting deadline ↗Mar 16, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Rodrigues DominicActivist (13D)Dec 8, 2025
- Pershing EdwardActivist (13D)Dec 1, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 18,505 | 1.0 | -97.7% |
| Apr 30, 2026 | 802,992 | 1.9 | -0.8% |
| Apr 15, 2026 | 809,494 | 2.1 | -5.3% |
| Mar 31, 2026 | 855,084 | 1.0 | +4.7% |
| Mar 13, 2026 | 817,047 | 2.1 | +1.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventApr 21, 2026
- Amended charter or bylawsFeb 2, 2026
- Shareholder voteJun 20, 2025
- Regulation FD disclosureJun 18, 2025
- Changed auditorApr 16, 2025
- Entered a material agreement · New financial obligation · Unregistered equity saleJan 22, 2025
- Entered a material agreementDec 26, 2024
- Other material eventDec 11, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.